Join
Live feed
·
PRReleasevia Quantisnow
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
RARE· Ultragenyx Pharmaceutical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RARE (Ultragenyx Pharmaceutical Inc.) and more on Quantisnow.